MetaStat, Inc. (OTCMKTS:MTST) Files An 8-K Other EventsItem 8.01.Entry into a Material Definitive Agreement.
On August 18, 2017, MetaStat, Inc. (“MetaStat”) received payment of $146,022 from Celgene Corporation (“Celgene”) for satisfactory completion of the third of four milestones to the pilot materials transfer agreement, as amended (the “Research Agreement”) between the parties.
MetaStat has successfully completed testing of Celgene’s proprietary materials in its nonclinical cell line models and is currently testing in its nonclinical animal models. Additionally, the term of the Research Agreement was extended by the parties through December 22, 2017. To date, MetaStat has received an aggregate of $876,134 from Celgene to the Research Agreement.
About MetaStat, Inc. (OTCMKTS:MTST)
MetaStat, Inc. is a pre-commercial molecular diagnostic company focused on the development and commercialization of diagnostics to provide oncologists and patients with clinically actionable information regarding the risk of systemic metastasis and adjuvant chemotherapy treatment decisions. The Company’s platform technologies are based on the identification of a pathway for the development of metastatic disease in epithelial-based solid tumors. It is developing two driver-based diagnostic product lines: MetaSite Breast and MenaCalc. Its MetaSite Breast and MenaCalc diagnostic product candidates are designed for patients based on their individual risk of metastasis. The MetaSite Breast test is applicable for early stage invasive breast cancer patients. The MenaCalc platform is a tissue-based quantitative immunofluorescence (QIF) assay applicable to a range of epithelial-based cancers, including breast, lung, colorectal and prostate.
